Chromosomal microarray reflex testing market set to reach $2.15 billion by 2030

By AI, Created 4:54 PM UTC, May 18, 2026, /AGP/ – The chromosomal microarray reflex testing market is projected to grow from $1.39 billion in 2025 to $2.15 billion by 2030, driven by rising genetic disorder awareness, prenatal screening demand and wider use of precision medicine. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through 2030.

Why it matters: - Chromosomal microarray reflex testing is becoming a bigger part of genetic diagnostics as providers look for more precise ways to detect chromosomal abnormalities and copy number variations. - The market’s growth signals rising demand for prenatal, oncology and rare disease testing, plus more use of genomic data in clinical decision-making.

What happened: - The chromosomal microarray reflex testing market was valued at $1.39 billion in 2025 and is projected to reach $1.51 billion in 2026. - The market is forecast to climb to $2.15 billion by 2030, based on a 9.1% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Market growth has been supported by greater awareness of genetic disorders, wider adoption of array comparative genomic hybridization, higher investment in molecular diagnostics and expanded hospital and laboratory infrastructure. - The market is also benefiting from demand for more precise prenatal testing. - Future growth is tied to next-generation sequencing-based arrays, personalized medicine, oncology and rare disease diagnostics, software for genomic data analysis, and high-throughput automated array platforms. - Emerging trends include high-resolution arrays, more pre- and post-natal genetic testing, SNP array integration with clinical workflows, customized multiplexed designs and broader oncology and rare disease use. - Chromosomal microarray reflex testing detects genome-wide copy number variations and chromosomal abnormalities, including deletions, duplications and structural alterations. - The test supports genetic counseling and helps clinicians make more informed decisions. - Rising genetic disorder prevalence is a key demand driver. - Delayed childbearing is increasing the number of pregnancies at higher risk for chromosomal abnormalities, including Down syndrome and other trisomies. - Chromosomal microarray testing can detect submicroscopic deletions, duplications and copy number variants that conventional karyotyping can miss. - The Cystic Fibrosis Trust reported that the number of people living with cystic fibrosis in the UK rose from 11,148 in 2022 to 11,318 in 2023. - Prenatal screening programs are also supporting demand. - The UK National Health Service reported a fetal anomaly ultrasound screening performance rate of 97.0% in the second quarter of 2024-2025. - Personalized medicine is another growth engine as care shifts toward treatments tailored to a patient’s genetics, environment and lifestyle. - The Personalized Medicine Coalition said the US FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022.

Between the lines: - The report points to a broader shift in diagnostics from broad screening toward more targeted, data-driven testing. - The strongest demand appears to be coming from settings where early detection changes care decisions, especially prenatal medicine and rare disease workups. - The combination of software, automation and higher-resolution arrays suggests the market is moving toward faster and more scalable lab workflows.

What’s next: - The report expects continued expansion as genetic testing becomes more integrated into routine care. - Growth should accelerate where health systems invest in prenatal screening, genomic infrastructure and precision medicine programs. - The next phase of the market will likely be shaped by broader adoption of automated platforms and more clinical use of SNP arrays and customized designs.

The bottom line: - Chromosomal microarray reflex testing is moving from a specialized diagnostic tool to a mainstream growth category in genomic medicine, with the strongest momentum coming from prenatal care, rare disease testing and precision medicine.